Related Experiment Video
Updated: Jun 23, 2026
13:18
Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
Published on: April 10, 2026
Pindolol augmentation enhances response outcomes in first depressive episodes
Maria J Portella1, Javier de Diego-Adeliño, Dolors Puigdemont
1Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain. mportella@santpau.cat
Summary
Pindolol augmentation of selective serotonin reuptake inhibitors (SSRIs) significantly enhances antidepressant response in first-episode depression. This combination therapy accelerates and improves treatment outcomes for initial depressive episodes.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- The effectiveness of adding pindolol to selective serotonin reuptake inhibitors (SSRIs) for depression treatment remains debated.
- Previous research indicated potential benefits in never-medicated patients and a trend for first-episode depression.
Purpose of the Study:
- To re-analyze data from a clinical trial investigating fluoxetine plus pindolol versus fluoxetine plus placebo.
- To specifically examine the impact of pindolol augmentation on sustained response rates and onset in first-episode versus recurrent depressive episodes.
Main Methods:
- Re-analysis of a randomized, double-blind, placebo-controlled trial comparing fluoxetine + pindolol with fluoxetine + placebo.
- Survival analysis was employed to assess the time to sustained response.
Main Results:
- Patients with a first depressive episode receiving fluoxetine + pindolol showed a significantly higher percentage of sustained responses (70.3%) compared to fluoxetine + placebo (44%).
- Survival analysis revealed that first-episode patients on fluoxetine + pindolol achieved sustained response significantly earlier (19 days) than those on fluoxetine + placebo (35 days).
- These beneficial effects of pindolol augmentation were not observed in patients with recurrent depressive episodes.
Conclusions:
- Pindolol augmentation appears to accelerate and enhance the early action of SSRIs, particularly in patients experiencing their first depressive episode.
- The findings suggest a specific benefit of pindolol addition for initial treatment of depression, with no observed effect on recurrent cases.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:24Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
01:27Depressive Disorders: MDD and Dysthymia
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...